GelStat acquires Mastix Medica
PALM CITY, Fla. – GelStat Corp. on Thursday announced it signed a definitive agreement to acquire Mastix Medica. The final closing of the acquisition is expected to take place on or before July 7.
The acquisition is is expected to add more than $500,000 in revenue in the third quarter ending Sept. 30, 2014, GelStat reported.
"The acquisition of Mastix Medica adds another dimension to GelStat that complements our present experience in product innovation and marketing," stated Larry Gershman, GelStat chairman and CEO. "The vertical integration also enhances our profitability of recently introduced dietary supplement Chews 2 Lose appetite suppressant gum. More importantly, the acquisition brings to GelStat a key asset and foothold in the explosive high CBD/low THC industrial hemp and medical marijuana market. We are also excited to be adding Bob Estey to our management team as he brings a wealth of financial management experience as well as manufacturing capabilities to the GelStat team."
Stanley Cup prediction: Rangers in 6
Lifetime New Yorker and DSN editor in chief Rob Eder took his second Mark Messier sighting in two days during the Stanley Cup finals as a positive omen: "Rangers in 6," says DSN’s supreme content creator. Eder spotted the former New York Rangers Captain at the corner of 57th Street and Lexington Avenue, Thursday afternoon, as he went for lunch. Two days earlier, on Tuesday evening, Eder spotted Messier at the corner of 55th Street and Park Avenue. This means one of two things: its a sign from the hockey gods, or Messier is stalking Eder.
What do you think? Tell DSN your Stanley Cup prediction in the comment section below or email firstname.lastname@example.org.
Study highlighting importance of MTM featured in Forbes
NEW YORK — Low-risk patients were three times less likely to be admitted to a hospital when they received medication therapy management from a pharmacist, according to the findings of a recent study that was highlighted in Forbes magazine.
“Enhancing the quality of care for patients has always been the goal of health care providers, but the growing costs of Medicare and health care in general have put an even brighter spotlight on strategies to improve patient outcomes and reduce unnecessary costs," he said.
Zillich led a team of researchers who collaborated with the home health care organization Amedisys and pharmacists from Curant Health (formerly HealthStat Rx), who provided the MTM intervention.
The study, led by Purdue University, underscores the important role that pharmacists can play in helping patients improve health outcomes.
"We know that medication therapy management (MTM) improves adherence, improves outcomes and improves lives," stated Patrick Dunham, CEO of Curant Health, which provided the medication therapy management interventions. "Reducing hospital admissions for the lowest-risk patients in this study by 86% is another powerful proof point for the value of MTM and its capability to simultaneously reduce costs and improve care across the health care continuum."
The study followed 895 patients from 40 Amedisys home health care centers throughout the United States, with 415 receiving the intervention.